KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,510,000 shares, an increase of 13.8% from the September 15th total of 5,720,000 shares. Based on an average daily volume of 381,900 shares, the short-interest ratio is currently 17.0 days.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV traded up $0.35 during mid-day trading on Wednesday, hitting $12.33. The company had a trading volume of 251,731 shares, compared to its average volume of 500,320. KalVista Pharmaceuticals has a 1-year low of $7.21 and a 1-year high of $16.88. The company has a market capitalization of $520.18 million, a PE ratio of -3.63 and a beta of 0.89. The business's 50-day simple moving average is $11.81 and its 200 day simple moving average is $12.07.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last announced its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, analysts expect that KalVista Pharmaceuticals will post -3.35 EPS for the current year.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 14,215 shares of the firm's stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the sale, the chief executive officer now directly owns 242,527 shares of the company's stock, valued at approximately $2,912,749.27. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Christopher Yea sold 7,102 shares of the company's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the transaction, the insider now directly owns 84,467 shares in the company, valued at approximately $1,014,448.67. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,215 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the sale, the chief executive officer now owns 242,527 shares of the company's stock, valued at $2,912,749.27. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,804 shares of company stock valued at $372,112 in the last quarter. Insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $153,000. Susquehanna Fundamental Investments LLC boosted its position in shares of KalVista Pharmaceuticals by 323.5% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company's stock worth $807,000 after acquiring an additional 52,347 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company's stock valued at $182,000 after acquiring an additional 3,314 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 2nd quarter worth about $15,768,000. Finally, Evoke Wealth LLC purchased a new stake in KalVista Pharmaceuticals during the second quarter worth approximately $181,000.

Wall Street Analyst Weigh In

KALV has been the subject of a number of research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.